ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 134 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.55 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,057,016 | -90.6% | 154,309 | -85.8% | 0.00% | -83.3% |
| Q2 2023 | $11,268,249 | +26.4% | 1,086,620 | -1.4% | 0.01% | +20.0% |
| Q1 2023 | $8,916,774 | -51.9% | 1,102,197 | -6.4% | 0.01% | -54.5% |
| Q4 2022 | $18,547,090 | +0.8% | 1,177,593 | +0.7% | 0.01% | 0.0% |
| Q3 2022 | $18,399,000 | +12.2% | 1,168,897 | -0.5% | 0.01% | +22.2% |
| Q2 2022 | $16,399,000 | -35.2% | 1,174,701 | -19.9% | 0.01% | -25.0% |
| Q1 2022 | $25,293,000 | +584.7% | 1,467,103 | +477.4% | 0.01% | +500.0% |
| Q4 2021 | $3,694,000 | -36.4% | 254,071 | -21.2% | 0.00% | -33.3% |
| Q3 2021 | $5,804,000 | -1.1% | 322,439 | -3.5% | 0.00% | 0.0% |
| Q2 2021 | $5,868,000 | -10.0% | 334,234 | +29.2% | 0.00% | -25.0% |
| Q1 2021 | $6,520,000 | +1434.1% | 258,711 | +294.2% | 0.00% | – |
| Q4 2020 | $425,000 | +151.5% | 65,628 | 0.0% | 0.00% | – |
| Q3 2020 | $169,000 | +59.4% | 65,628 | 0.0% | 0.00% | – |
| Q2 2020 | $106,000 | +158.5% | 65,628 | +68.2% | 0.00% | – |
| Q1 2020 | $41,000 | -43.8% | 39,023 | -1.6% | 0.00% | – |
| Q4 2019 | $73,000 | +711.1% | 39,651 | +327.3% | 0.00% | – |
| Q3 2019 | $9,000 | -99.1% | 9,279 | -98.0% | 0.00% | -100.0% |
| Q2 2019 | $992,000 | +90.0% | 453,969 | +419.3% | 0.00% | – |
| Q1 2019 | $522,000 | +18.1% | 87,411 | +46.0% | 0.00% | – |
| Q4 2018 | $442,000 | -95.0% | 59,858 | -90.1% | 0.00% | -100.0% |
| Q3 2018 | $8,793,000 | +20.7% | 605,674 | +66.0% | 0.00% | +50.0% |
| Q2 2018 | $7,285,000 | +327.3% | 364,843 | +274.6% | 0.00% | +100.0% |
| Q1 2018 | $1,705,000 | -61.5% | 97,401 | -45.8% | 0.00% | -66.7% |
| Q4 2017 | $4,426,000 | +23.6% | 179,622 | +29.4% | 0.00% | +50.0% |
| Q3 2017 | $3,581,000 | +10.6% | 138,838 | +16.2% | 0.00% | 0.0% |
| Q2 2017 | $3,239,000 | +20.5% | 119,529 | +32.6% | 0.00% | 0.0% |
| Q1 2017 | $2,687,000 | -10.2% | 90,161 | -18.2% | 0.00% | 0.0% |
| Q4 2016 | $2,991,000 | +126.4% | 110,283 | +113.7% | 0.00% | +100.0% |
| Q3 2016 | $1,321,000 | +96.9% | 51,595 | +41.8% | 0.00% | – |
| Q2 2016 | $671,000 | +4093.8% | 36,377 | +4110.3% | 0.00% | – |
| Q1 2016 | $16,000 | -57.9% | 864 | -40.2% | 0.00% | – |
| Q4 2015 | $38,000 | – | 1,446 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |